Providing consistent, quality care for patients with metastatic castration-resistant prostate cancer (mCRPC) in an ever-changing therapeutic landscape is complex and challenging. Watch this on-demand video, which offers key insights on applying VA Oncology Clinical Pathways-recommended risk stratification and molecular testing, evaluating evidence-based treatment options, and managing toxicities associated with targeted therapies. Gain expert strategies for addressing care gaps and advancing patient-centered care for veterans with mCRPC.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/advancing-latest-evidence-mcrpc-treatment-across-va-clinical-care-teams
- Start Date: 2024-11-19 06:00:00
- End Date: 2024-11-19 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 92500.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 20000.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 35000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest